Literature DB >> 10618529

Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes.

A Arkema1, A Huckriede, P Schoen, J Wilschut, T Daemen.   

Abstract

Priming of cytotoxic T lymphocyte (CTL) activity with exogenous antigen requires introduction of the antigen into the MHC class I presentation pathway of antigen-presenting cells. In the present study, we used fusogenic reconstituted envelopes (virosomes), derived from influenza virus, as a carrier system for delivery of a synthetic soluble peptide corresponding to a major murine CTL epitope of the influenza virus nucleoprotein (NP). Virosomes containing encapsulated NP-peptide efficiently sensitized target cells for recognition by influenza-specific CTLs generated through priming of mice with infectious virus. Intramuscular immunization of mice with peptide-containing virosomes induced a potent class I MHC-restricted CTL response against influenza-infected target cells. By contrast, an equal dose of NP-peptide encapsulated in fusion-inactivated virosomes did not induce CTL activity, indicating an essential role of the membrane fusion activity of the virosomes in the induction of the response. Likewise, NP-peptide encapsulated in liposomes, NP-peptide mixed with empty virosomes and NP-peptide in IFA failed to induce a CTL response. These results demonstrate that fusion-active virosomes represent a promising delivery system for induction of class I MHC-restricted CTL activity with non-replicating viral antigens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618529     DOI: 10.1016/s0264-410x(99)00404-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine.

Authors:  Peter C Soema; Sietske K Rosendahl Huber; Geert-Jan Willems; Wim Jiskoot; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  Pharm Res       Date:  2014-10-25       Impact factor: 4.200

Review 2.  Development of cross-protective influenza a vaccines based on cellular responses.

Authors:  Peter Christiaan Soema; Elly van Riet; Gideon Kersten; Jean-Pierre Amorij
Journal:  Front Immunol       Date:  2015-05-15       Impact factor: 7.561

3.  Small Wonders-The Use of Nanoparticles for Delivering Antigen.

Authors:  Aya Taki; Peter Smooker
Journal:  Vaccines (Basel)       Date:  2015-08-10

4.  Whole-Inactivated Influenza Virus Is a Potent Adjuvant for Influenza Peptides Containing CD8+ T Cell Epitopes.

Authors:  Peter C Soema; Sietske K Rosendahl Huber; Geert-Jan Willems; Ronald Jacobi; Marion Hendriks; Ernst Soethout; Wim Jiskoot; Jørgen de Jonge; Josine van Beek; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  Front Immunol       Date:  2018-03-14       Impact factor: 7.561

Review 5.  Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation.

Authors:  Saborni Chattopadhyay; Jui-Yi Chen; Hui-Wen Chen; Che-Ming Jack Hu
Journal:  Nanotheranostics       Date:  2017-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.